Alzamend Neuro reports FY25 net cash provided by financing activities of $10.4M

Alzamend Neuro (ALZN) reported its financial results for the year ended April 30, 2025, which were disclosed on an annual report on Form 10-K filed on July 22, 2025, with the Securities and Exchange Commission. Alzamend has strengthened its financial position, reflecting a strategic focus on fiscal prudence and effective capital management. Key financial highlights include: Net cash provided by financing activities of $10.4 million for the year ended April 30, 2025; Stockholder equity of $3.9 million at April 30, 2025, compared to a stockholder deficit of $2.6 million at April 30, 2024; Cash of $3.9 million at April 30, 2025, compared to $0.4 million at April 30, 2024; and Total liabilities of $0.6 million at April 30, 2025, compared to $3.2 million at April 30, 2024. “The successful completion of this Financing, months ahead of schedule, reflects confidence in our mission and strong belief in our vision,” said Stephan Jackman, Chief Executive Officer of Alzamend. “The capital raised will be used to support the five Phase II clinical trials of AL001 “Lithium in Brain” Studies in partnership with Massachusetts General Hospital and Harvard Medical School.”